The new production plant in Spain will scale up production. The Company is also going to build a research & development center in biotechnology and cultivated protein in Brazil
JBS, the largest global protein company and the world’s second-largest food industry, has entered into an agreement to acquire control of Spanish company BioTech Foods. The deal signals the company’s entry into the cultivated protein market, which consists of producing food from animal cells and includes investment in building a new production plant in Spain to scale up production. Along with the acquisition, JBS is also announcing the setting up of Brazil’s first cultivated protein research & development (R&D) center. In all, JBS will channel US$ 100 million to the two projects.
Founded in 2017, BioTech Foods is one of the leaders in the development of biotechnology for producing cultivated protein, and has the support of the Spanish government and the European Union. The company operates a pilot plant in the city of San Sebastián and expects to reach commercial production in mid-2024 with the building of this new production plant. The investment in the new facilities is estimated at US$ 41 million.
BioTech Foods is founded by Iñigo Charola, a sales executive with broad experience in marketing and strategy, and Mercedes Vila Juárez, PhD in materials physics and one of the world’s leading experts in the use of materials for biomedicine. In 2010, she was awarded with the Lóreal-UNESCO Award “For Women in Science” as recognition of her scientific career. Charola holds the position of BioTech’s CEO and Mercedes, as Company’s CTO.
Under the terms of the deal, JBS becomes the majority shareholder of BioTech Foods. The deal enables both companies to pool their strengths and accelerate the development of the cultivated protein market. The Brazilian company will now have access to the technology and to the protein production of BioTech Foods which, in turn, will have at its disposal the industrial processing capacity, marketing structure and sales channels of JBS for bringing the new product to market.
When commercial operations begin, the cultivated protein will reach consumers in the form of prepared foods, like hamburgers, steaks, sausage meats, and meatballs, among others, with same quality, safety, taste and texture as in traditional protein. The technology has the potential not only for the production of bovine protein, but also chicken, pork and fish.
“This acquisition strengthens our strategy of innovation, from how we develop new products to how we commercialize them, to address the growing global demand for food. Combining technological know-how with our production capacity, we will be in a position to accelerate the development of the cultivated protein market”, contends Gilberto Tomazoni, Global CEO of JBS.
The acquisition of BioTech Foods is still subject to confirmation by the foreign investment authority of Spain, among other conditions common to this type of transaction.
The initiative in Europe is being supplemented by the cultivated protein research center in Brazil. Due to be inaugurated in 2022, the second phase of the center will include a plant occupying an area of 10 thousand square meters. Headed up by Luismar Marques Porto and Fernanda Vieira Berti, both Ph.D. in chemical engineering, the initiative will have around 25 researchers and will work on the development of leading-edge technologies for the food industry.
Two of Brazil’s major specialists in bioengineering, both professors have extensive international professional and academic experience. While Porto was a visiting scientist at Harvard University and the Massachusetts Institute of Technology (MIT), Fernanda has been at the Research Institute I3Bs and created a startup incubated in Silicon Valley (USA) and which operates in Europe developing products based on regenerative and T-cell medicine for treating animals.
Through the investment in the R&D center, JBS intends to develop new techniques that accelerate the economies of scale and reduce the costs of producing cultivated protein, bringing forward its commercialization on the market.
“We are expanding our global platform to address the new trends in consumption and the growth of the global population. The acquisition of BioTech Foods and the new research center put JBS in a unique position to push ahead in the cultivated protein sector”, adds Tomazoni.
Leader in beef, pork and chicken, the Company has made other important moves during 2021 to expand its operation in other proteins: it has acquired Dutch company Vivera, Europe’s largest independent plant-based food company, and it has just concluded the acquisition of Huon, the second-largest salmon producer in Australia. Cultivated protein has arrived to supplement this portfolio.
JBS’ entry into the cultivated protein market had the strategic support of The Good Food Institute, an entity that promotes plant and cell-based alternatives to animal products. “We, at GFI, were delighted to have been asked to collaborate on the JBS Cultured Protein project. We were able to offer strategic, technological, regulatory support as well as connections with scientists and startups. Our goal is always to facilitate the entry of new agents so that the world of alternative proteins can develop faster. We were privileged to see the company leverage these resources to seek leadership in the area, generating one of the most daring strategies in the history of the sector. It was an honor to see this project born and learn from the JBS executive team during the planning process”, says Gustavo Guadagnini, president of GFI Brazil.